FDA approves new antibiotic to treat community-acquired pneumonia

The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia. The antibiotic, Xenleta, received priority review under an FDA Safety and Innovation Act designation for drug products intended to treat serious or life-threatening infections. About 1 million people are hospitalized with community-acquired pneumonia annually in the United States. “For managing this serious disease, it is important for physicians and patients to have treatment options,” said Ed Cox, M.D., director of FDA’s Office of Antimicrobial Products. “This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics.”
Related News Articles
Headline
Measles cases have been reported by 42 states and jurisdictions this year, with 1,563 total nationwide, according to the latest data released yesterday by the…
Headline
Inova Health System’s Toni Ardabell, chief of clinical enterprise operations, and Sage Bolte, Ph.D., chief philanthropy officer and president of the Inova…
Perspective
All of America’s hospitals and health systems, regardless of ownership status, size or location, provide a vast range of benefits, programs and essential…
Headline
Speakers interested in leading conversations and collaborations at the AHA’s new Healthier Together Conference are advised to submit a content proposal by Sept…
Blog
In this insightful conversation hosted by Nancy Myers of the American Hospital Association, we explore how Owensboro Health (Ky.) and CredibleMind are…
Headline
The AHA will accept applications through Oct. 14 for the 2026 AHA Dick Davidson NOVA Award. This award recognizes hospitals and health systems that demonstrate…